Miracell selected as one of the “1000 National Innovative Companies in the Health and Diagnostics Sector”
A stem cell specialist dedicated to research and development
Stem cell specialist Miracell has been selected as one of the government’s “1,000 Leading Innovative Companies.”
Miracell (CEO Shin Hyun-soon) announced on the 1st that it was selected for the third round of the “1,000 Leading Innovative Companies,” a program announced by the Financial Services Commission based on evaluations by nine government ministries, including the Ministry of Trade, Industry and Energy and the Ministry of Health and Welfare.
The “1,000 Leading Innovative Companies” program, launched on July 30, 2020, was approved at the 12th meeting of the Central Disaster and Safety Countermeasures Headquarters. The program selects leading innovative companies by industry and provides them with exceptional financial support to foster them as future core companies.
Starting with 32 companies in the first round, 247 were selected in the second round, and 321 companies have been selected this time. The Financial Services Commission plans to select 1,000+ representative innovative companies from each industry by 2022.
Miracell was selected as one of the “Health and Diagnostic Innovative Companies” in the health technology, medical device, and innovative pharmaceutical sectors, based on selection criteria established by the Ministry of Health and Welfare.
Launched in 2009 with the introduction of Harvard University’s cell extraction technology, Miracell successfully developed a “minimally manipulated stem cell isolation and amplification source technology” in 2017. The Ministry of SMEs and Startups selected this technology for a small business commercialization technology development project.
Based on this technology, Miracell successfully localized and independently developed the SMART M-CELL2 kit, a replacement for the SmartPReP2 kit developed by the Harvard Medical School’s Immunology Research Institute in 2018 and exported globally.
Test results at Seoul National University Bundang Hospital showed that Miracell’s performance was comparable to or even superior to that of SmartPReP.
Smart Mcell 2 is a device that extracts large quantities of automatically separated stem cells from bone marrow blood extracted from the body through centrifugation. It is currently used in major hospitals both domestically and internationally.
CEO Shin Hyun-soon (pictured) stated, “Being selected as a National Representative Innovative Company is very significant. It opens up new avenues for scientifically treating rare and intractable diseases, including Parkinson’s disease and intractable chronic renal failure, using stem cells.”
He continued, “Stem cell therapy involves extracting bone marrow blood from the patient, concentrating it through centrifugation, extracting a large quantity of stem cells, and then reinjecting them into the body. Because old cells regenerate into healthy ones, it is highly effective in improving bodily functions in the affected area.”
Recognized as an innovative technology, Smart Mcell 2 is a cutting-edge system for “bone marrow and blood stem cell manufacturing,” using biological pharmaceutical manufacturing technology to extract hematopoietic stem cells (CD34+) from blood and mesenchymal stem cells from bone marrow.
Approximately 2.9 billion cells can be isolated and extracted in less than an hour, with a cell viability rate of 80-98%.
Its automated system features a closed, air-tight system that prevents cell deformation.
Smart Mcell 2 features a special LED to enhance cell activity, transitioning from analog to digital.
It also features voice support, making it a perfect fit for cutting-edge bio-healthcare medical devices.
Meanwhile, Miracell, which began its medical business in 1986, has been dedicated to research and development as a stem cell specialist since 2007.
In particular, our biological drug manufacturing technology has been certified by the Ministry of Health and Welfare as a new medical technology that helps treat conditions such as acute myocardial infarction, critical limb ischemia, and cartilage defects. Furthermore, we have secured core technologies through GMP, ISO13485, ISO9001, and CE certifications, and 22 patent applications for cell extraction technology.